Development
AstraZeneca PLC
AZN
$73.01
$0.130.18%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 45.81B | 44.99B | 44.48B | 43.84B | 44.35B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.81B | 44.99B | 44.48B | 43.84B | 44.35B |
| Cost of Revenue | 8.04B | 4.87B | 5.80B | 6.88B | 8.62B |
| Gross Profit | 37.77B | 40.12B | 38.68B | 36.96B | 35.73B |
| SG&A Expenses | 18.54B | 17.66B | 17.63B | 17.38B | 17.42B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.02B | -964.00M | -1.00B | -338.00M | -361.00M |
| Total Operating Expenses | 35.96B | 31.48B | 32.26B | 33.67B | 35.35B |
| Operating Income | 9.86B | 13.52B | 12.23B | 10.17B | 9.00B |
| Income Before Tax | 6.90B | 6.78B | 6.05B | 4.21B | 2.50B |
| Income Tax Expenses | 938.00M | 876.00M | -118.00M | -499.00M | -792.00M |
| Earnings from Continuing Operations | 5.96K | 5.90K | 6.17K | 4.71K | 3.29K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -6.00M | -8.00M | -6.00M | -4.00M | -5.00M |
| Net Income | 5.96B | 5.90B | 6.16B | 4.70B | 3.29B |
| EBIT | 9.86B | 13.52B | 12.23B | 10.17B | 9.00B |
| EBITDA | 14.43B | 18.18B | 16.98B | 15.11B | 13.94B |
| EPS Basic | 3.84 | 3.81 | 3.98 | 3.04 | 2.12 |
| Normalized Basic EPS | 3.47 | 4.95 | 4.42 | 3.62 | 3.13 |
| EPS Diluted | 3.82 | 3.79 | 3.96 | 3.02 | 2.11 |
| Normalized Diluted EPS | 3.44 | 4.91 | 4.39 | 3.60 | 3.11 |
| Average Basic Shares Outstanding | 6.20B | 6.20B | 6.20B | 6.20B | 6.19B |
| Average Diluted Shares Outstanding | 6.24B | 6.24B | 6.24B | 6.24B | 6.24B |
| Dividend Per Share | 2.90 | 2.90 | 2.90 | 2.90 | 2.90 |
| Payout Ratio | 75.25% | 75.97% | 72.41% | 94.39% | 132.77% |